In contrast to the aforementioned strategies, I first explored the drug candidates, focusing on the basis of comprehensively reversing DDX3X-dependent downstream gene signatures, and characterized chaetocin as one of potential targets for therapeutics in liver cancer. Here, DDX3X is linked to liver cancer.